Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

NCT06253663 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Mantle Cell Lymphoma
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Interventions

DRUG: KTE-X19
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Kite, A Gilead Company